TP53 and cancer: Since MDM2-mediated p53 inhibition is a main inhibitory mechanism in tumors retaining wild-type p53, targeting the MDM2-p53 interaction by small molecules, like Nutlin-3a, represents a novel potential therapeutic strategy to reactivate p53 in cancer [42].